Zealand Pharma Boosts Investor Confidence with $200M Buyback and Roche Milestone Payments

Zealand Pharma unveiled a $200 million buyback plan and anticipated $700 million in milestone payments from Roche. This strategic move boosts investor morale, counteracting disappointment from previous trial results. The company remains committed to its research and development investments, ensuring its pipeline's integrity without cuts to R&D spending.

Zealand Pharma announced on Thursday its plans for a $200 million share buyback, alongside projected milestone payments worth $700 million from Roche, effectively restoring investor confidence following previous disappointments in mid-stage trial outcomes.

The initiative marks a strategic pivot from March when concerns overshadowed Zealand’s petrelintide obesity drug, primarily aimed at competing with Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The drug targets a novel hormone pathway, which could mean reduced side effects for users.

The firm's CFO, Henriette Wennicke, reaffirmed commitment to research spending, stating the firm would invest $800 million over five years without compromising on R&D. Zealand's unfaltering belief in its drug development capabilities is evidenced by maintaining 2026 expense guidance and reporting steady funding support.